What Is the LFSC ETF? Returns, Expense Ratio, Holdings, and Alternative ETFs at a Glance
The F/m Emerald Life Science Innovation ETF (ticker: LFSC) is an actively managed fund that invests in innovative life science companies. It does not track an index. Instead, its sub-adviser selects holdings directly, and exposure to biotech and pharmaceutical stocks and high growth potential are the key points of the investment outlook.
What Is the F/m Emerald Life Science Innovation ETF?
This is an actively managed ETF that does not track a predetermined index. Instead, its sub-adviser directly selects and holds life science companies with innovative growth potential.
It suits investors who are drawn to the growth prospects of the biotech, pharmaceutical, and medical device sectors and who have confidence in active management.
The ETF is managed actively by F/m Investments.
How Does the F/m Emerald Life Science Innovation ETF Invest?
| Item | Details |
|---|---|
| Management style | Active (stock selection by sub-adviser) |
| Investment sector | Life sciences (biotech, pharmaceuticals, medical devices) |
| Rebalancing frequency | As needed (at the discretion of active management) |
| Dividend frequency | To be confirmed |
| Total expense ratio | 0.54% |
The fund invests most of its net assets in stocks of innovative life science companies. With no predetermined index, the sub-adviser directly picks stocks with strong growth potential regardless of company size.
- An active stock selection strategy rather than passive index tracking
- A concentrated portfolio specialized in the life science sector
F/m Emerald Life Science Innovation ETF Size and Costs (AUM and Management Fee)
Assets under management (AUM) are $120.6M, and the total expense ratio is 0.54% per year.
Compared with active healthcare and biotech ETFs in the same category such as ARKG, it differs in fund size and fee structure.
F/m Emerald Life Science Innovation ETF Performance and Trends
The life science and biotech sector tends to be highly volatile depending on clinical trial results and regulatory approval events, and this ETF also reacts sensitively to issues affecting individual holdings.
As an actively managed healthcare theme ETF, its fund flows are heavily influenced by shifts in investor sentiment toward the biotech sector and by clinical and regulatory news. Given the nature of a small active fund, the swings in fund flows are also relatively large.
F/m Emerald Life Science Innovation ETF Strengths and Weaknesses
Its strength is actively selected exposure to innovative life science companies, while managing liquidity and volatility is a challenge given its nature as a small active fund.
💪 Key Strengths
⚠️ Points to Watch
Alternative ETFs and Related Products to the F/m Emerald Life Science Innovation ETF
Among ETFs classified under the same active healthcare and biotech theme, ARKG specializes in genomic innovation, while sector rotation active ETFs such as XLSR and SSUS differ in that they rotate through several sectors beyond life sciences. As direct alternatives to an active life science strategy, you can also look at biotech index ETFs such as XBI and leveraged biotech theme products.
| Ticker | Name | Price | Change | AUM | Total Expense Ratio | Dividend Yield | 1Y |
|---|---|---|---|---|---|---|---|
| Roundhill Magnificent Seven ETF | $66.42 | -0.8% | $4.9B | 0.30% | 1.47% | +2.6% | |
| Fundstrat Granny Shots US Large Cap ETF | $25.01 | -1.1% | $3.8B | 0.75% | 0.14% | +3.0% | |
| ARK Genomic Revolution ETF | $40.50 | -0.3% | $1.8B | 0.75% | - | +50.7% | |
| State Street US Sector Rotation ETF | $63.20 | -1.2% | $1.1B | 0.70% | 0.42% | +4.4% | |
| iShares U.S. Industry Rotation Active ETF | $34.83 | -0.8% | $590.7M | 0.42% | 0.62% | +10.8% |
| Ticker | Name | Weight | Price | Change | Market Cap | P/E | Dividend Yield |
|---|---|---|---|---|---|---|---|
| Cogent Biosciences Inc | 0.23% | $27.85 | +1.5% | $4.8B | - | - | |
| Travere Therapeutics Inc | 0.16% | $51.10 | +2.8% | $4.9B | - | - | |
| LivaNova PLC | 0.21% | $91.92 | -0.6% | $5.1B | 26.4 | - | |
| Corcept Therapeutics Inc | 0.07% | $70.03 | +1.2% | $7.7B | 55.3 | - | |
| Spyre Therapeutics Inc | 0.07% | $93.81 | -5.6% | $8.9B | - | - |
F/m Emerald Life Science Innovation ETF Investor Checkpoints
These are points for reviewing the characteristics of an active life science ETF before investing in LFSC. Unlike products that passively track an index, you should check sector concentration, fund size, and active management performance together in advance.
| Checkpoint | What to check | Current status |
|---|---|---|
| 💵 Expense ratio | Check the fee level relative to passive funds, given the nature of active management | Fees apply |
| 🧬 Sector concentration | Whether the fund is skewed toward the single life science sector | Concentrated portfolio maintained |
| 💧 Liquidity | Trading volume and bid-ask spread of a small active fund | Relatively limited |
| 📊 Management performance | Performance of the active selection strategy versus its benchmark | Ongoing monitoring needed |
The life science sector is highly volatile in the short term depending on clinical trial results and regulatory approvals, and because of active management, a gap versus the benchmark may arise depending on stock selection results.
This is a theme ETF suited to investors who want active exposure to innovative life science companies. Sector concentration risk and relatively limited liquidity are factors to consider before investing.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. All investment responsibility lies with the investor.
This article reflects information as of July 2, 2026.